Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go:
Expired
investment:
Withheld
The Stirling Electric Motorcycle Company presents a futuristic motorcycle experience available today! The SEMC "SINATRA" delivers an exhilarating ride, easy maintenance, and the finest ride quality in its category. Whether you're a new, returning, or transitioning rider, enjoy the benefits of electric riding without the complexities and costs of advanced licensing. In numerous regions, motorcycles with up to 11 kilowatts of continuous power have more lenient licensing rules, such as in the UK where an 11kw SINATRA can be legally ridden after completing a one-day basic training course.
days to go:
Expired
investment:
£42,000
Beacon is a company that offers software and supporting services to help a client optimise their digital marketing efforts and improve their marketing Return-on-Investment (ROI). The company offers clients services like campaign management, PPC (Pay Per Click) campaign analytics, social media analytics, and anti-fraudulent click system etc. Using the company's portal, marketers can compare costs and revenue across all digital channels, channel by channel, and with their off-line marketing efforts. Beacon aims at removing ‘non-human clicks’ and giving direct independent attribution of emails, posts, ad’s, etc. to specific website actions and business goals thereby improving engagement and reducing costs. According to Stratistics Market Research Consulting, the web analytics tools market is expected to reach $4.9 billion by 2022, growing at a Compound Annual Growth Rate (CAGR) of 20.8%, in which, Beacon aims to be a leading contender. The company will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£240,000
Intelligent Health aim to get the whole community active by providing games and incentives such as ''beat the street''. By providing schools and communities with friendly competition to walk and cycle more by tapping their cards on ''beat boxes'', and with prizes and league tables on offer, Intelligent health are bringing communities together.
days to go:
Expired
investment:
£700,000
Metal matrix composite components and materials, primarily comprised of aluminium for use in the engineering and manufacturing industries. Alvant specialise in designing, developing and producing the composite for well-known clients such as Ford and Safran.
In the last financial year, Alvant achieved a turnover of almost £617k and has invested more than £10m towards manufacturing and testing their own product. Alvant is now raising funds to distribute their components to a wider market and expand the number of commercial applications that would benefit from their materials.
days to go:
Expired
investment:
£2,105,001
Book Your Lifestyle (BYL) are a marketplace for the hair and beauty services market. BYL brings together the supplier and the consumer. The supplier can market their business, fill their unsold slots and improve the efficiency of their booking systems. BYL make it much easier for the consumer to book their hair appointment on the go, on their mobile and also allows them to make payments.
days to go:
Expired
investment:
£655,000
Invluencer is a Venture Capital (VC) company with an economic model designed to bring VC to the masses. Invluencer believes in boosting greater investment capability between investors and company representatives. This is undertaken by creating a smart-contract enabled 'Intelligent Wallet' for autonomous investment in vetted high-growth companies facilitated by Invluencer’s unique Multi-Asset Platform (I-MAP) and Intelligent Distributed Due Diligence (i3D) platform. Through these platforms, the company aims to simplify investment and open liquidity between worthy companies and accredited investors. The company will use the investments to continue the development of due diligence and fund management platforms, strengthen the investment team and analysis team, strengthen relationships and partnerships within the VC ecosystem.
days to go:
Expired
investment:
£154,000
Evershare.io is a platform that enables fans to own a share of an artist's music income under Income Share Agreements (ISA). An ISA is an agreement between the recipient and the donors whereby the recipient agrees to share a percentage of the income generated from their project that they have raised money for. Using blockchain technology, the company is building a new way for artists and fans to engage and share the journey to musical success. For just £12 a year, an artist or band can submit their music to Evershare upon which the customer service team will help the artists or band to release their music tracks across major streaming companies such as Apple Music, Spotify, and Deezer. The artists also get to keep 100% of royalties they earn from the release of their albums or singles. They will use the investment to support and bring talent that is less heard or unknown to fans and break the unhealthy oligopoly that exists in the music publishing industry.
days to go:
Expired
investment:
Withheld
Cable Software Limited (“Cable Software” or the “Company”) aspires to become the recognised B2B cloud based procurement exchange across the high-end regulated medi-markets. Initially, the Company is focusing upon the dental market before moving into veterinary, ophthalmic and general medicine. Helping dentists to work closely together.
days to go:
Expired
investment:
£10,000
Ceryx Medical is a medical technological entity that is developing bioelectronics based on a unique, patent-protected, chip technology that can mimic nerve centres within the body called Central Pattern Generators (CPGs). CPGs help to control a range of autonomic or rhythmical processes within the body such as peristalsis, heart rate, and even walking. The Ceryx system resembles a traditional cardiac pacing device that holds a lot of promise in potentially alleviating incidences of heart failure leading to a therapeutic effect on patient health. In the UK, this is a day surgery procedure under local anaesthetic with a basic system costing around £3500. The device, therefore, offers a cost-effective, single procedure solution for this currently intractable disease. Treatment expenditures on heart failure cases in the EU amount to almost £35 billion. The Ceryx system is a potential disruptor in this segment and offers multiple potential applications. The company is targeting £500,000 as part of £1 million round. With the investment, the company aims to produce a data package that mimics those used to support 510k/NDA applications, as mandated by the US Food and Drug Administration (FDA), for current devices and drugs used to treat heart failure.
days to go:
Expired
investment:
Withheld
